STOCK TITAN
  1. Home
  2. Sec-filings
  3. PCVX
  4. [Form 4] Vaxcyte, Inc. Insider Trading Activity

Vaxcyte (PCVX) director granted RSUs and 11,389-share stock option

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Vaxcyte, Inc. director Anne S. Drapeau reported equity compensation awards rather than market trades. She received 2,265 shares of Common Stock in the form of restricted stock units, bringing her direct Common Stock holdings to 12,481 shares after the grant.

She was also granted a stock option for 11,389 shares of Common Stock at an exercise price of $49.56 per share, expiring on June 15, 2036. Both the RSUs and the option are scheduled to vest fully on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration and her continuous service.

Positive

  • None.

Negative

  • None.
Insider Drapeau Anne S
Role null
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 11,389 $0.00 --
Grant/Award Common Stock 2,265 $0.00 --
Holdings After Transaction: Stock Option (right to buy) — 11,389 shares (Direct, null); Common Stock — 12,481 shares (Direct, null)
Footnotes (1)
  1. Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date.
RSU grant 2,265 shares Restricted stock units granted to director on June 15, 2026
Common shares held 12,481 shares Total Vaxcyte Common Stock directly held after grant
Option grant size 11,389 shares Stock option covering Common Stock granted June 15, 2026
Option exercise price <money>$49.56</money> per share Conversion or exercise price of stock option
Option expiration <date>June 15, 2036</date> Expiration date of the stock option award
Full vesting date <date>June 15, 2027</date> Latest date for full vesting of RSUs and option, absent earlier meeting
restricted stock units ("RSUs") financial
"Represents the number of shares of Common Stock underlying restricted stock units ("RSUs")."
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
Stock Option (right to buy) financial
"security_title: "Stock Option (right to buy)" with underlying Common Stock shares."
exercise price financial
"conversion_or_exercise_price: "49.5600" as the exercise price per share of the option."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vest monthly financial
"The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 15, 2027..."
continuous service financial
"subject to the Reporting Person's continuous service through such date."
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Drapeau Anne S
(Last)(First)(Middle)
C/O VAXCYTE, INC.
825 INDUSTRIAL ROAD, STE. 300
(Street)
SAN CARLOS CALIFORNIA 94070
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Vaxcyte, Inc. [ PCVX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/15/2026A2,265(1)A$012,481D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$49.5606/15/2026A11,389 (2)06/15/2036Common Stock11,389$011,389D
Explanation of Responses:
1. Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date.
2. The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date.
Remarks:
Anne S. Drapeau, by /s/ Peter N. Efremenko, Attorney-In-Fact06/16/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Vaxcyte (PCVX) director Anne S. Drapeau report?

Anne S. Drapeau reported equity compensation grants, not market trades. She received 2,265 restricted stock units and a stock option covering 11,389 shares of Vaxcyte Common Stock, both awarded at no cash cost to her on the grant date.

How many Vaxcyte (PCVX) shares does Anne S. Drapeau hold after this Form 4?

Following the reported grant, Anne S. Drapeau directly holds 12,481 shares of Vaxcyte Common Stock. This total reflects the addition of 2,265 restricted stock units reported as Common Stock underlying RSUs in the filing’s non-derivative transaction table.

What are the key terms of Anne S. Drapeau’s new Vaxcyte stock option?

She received a stock option for 11,389 shares of Common Stock with an exercise price of $49.56 per share. The option expires on June 15, 2036 and vests monthly, fully vesting on the earlier of June 15, 2027 or the day prior to the next annual stockholders’ meeting.

How do the new Vaxcyte RSUs granted to Anne S. Drapeau vest?

The 2,265 restricted stock units each represent the contingent right to one Vaxcyte Common Share. They will fully vest on the earlier of June 15, 2027 or the day prior to the next annual stockholders’ meeting, assuming her continuous service and subject to any acceleration provisions.

Does this Vaxcyte (PCVX) Form 4 show insider buying or selling on the market?

The Form 4 shows compensation-related equity awards, not open-market buying or selling. All transactions are coded as grants or awards, with zero purchase price per share and no reported sales or tax-withholding dispositions in the transaction summary.